| Ytd | 104.27% | |
| 1y | 166.56% |
| Open | 16.38 | Prev Close | 16.40 | Low | 16.08 | High | 16.50 | Mkt Cap | 1.74B |
| Vol | 330.12K | Avg Vol | 4.08M | EPS | -1.09 | P/E | N/A | Forward P/E | -17.42 |
| Beta | 2.31 | Short Ratio | 2.30 | Inst. Own | 66.77% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 14.97 | 200-d Avg | 10.19 | 1yr Est | 15.44 |
This whale alert can help traders discover the next big trading opportunities. Whales are entities w
Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA
On August 20, 2026, Personalis, Inc. received a new task order under its contract with the U.S. Depa
Treasury's expanded long-bond buybacks knocked yields off 20-month highs and sank the dollar, as
Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.30) per share which missed the analyst con
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a lo
Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full de
Tempus AI stock has fallen about 16% YTD. Cathie Wood still owns it as ARKK's 4th largest holdin
Lake Street analyst Thomas Flaten downgrades Personalis (NASDAQ:PSNL) from Buy to Hold and announ
BTIG analyst Mark Massaro maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price targ
Tempus AI stock falls after a $1.5 billion Personalis deal expands its reach in the $20 billion MRD
Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal dat
Needham analyst Mike Matson maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price ta
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-
This critical regulatory milestone enables the clinical use of Personalis’ ultrasensitive Minimal Re
Morgan Stanley analyst Tejas Savant maintains Personalis (NASDAQ:PSNL) with a Equal-Weight and ra
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announce
Personalis, Inc. (NASDAQ:PSNL) today announced clinical data from the 2026 American Society of Clini
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announce
Personalis wins expanded Medicare coverage for NeXT Personal MRD test in breast cancer patients unde
Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan Americ
Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares o
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings a
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
On Wednesday, 311 stocks hit new 52-week lows.
Friday's session saw 112 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
Friday's session saw 169 companies set new 52-week lows.
Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly ea